EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer

Kunpeng Fang, Jie Wang, Jianyong Yuan, Chengjun Sui, Jiajun Zhi, Yong Xia, Minmin Sun

Cancer Reports · 2024

DOI: 10.1002/cnr2.1952 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Kunpeng Fang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Special Treatment I, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China. Hauptthemen laut MEDLINE: Intestinal Perforation, Colorectal Neoplasms, Rectal Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Program of Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the risk factors for gastrointestinal perforation in metastatic colorectal cancer patients receiving bevacizumab.

Methods

We retrospectively reviewed 217 patients with metastatic colorectal cancer receiving bevacizumab to investigate the risk factors for gastrointestinal perforation. Three patients occurred intestinal perforation after receiving bevacizumab. We analyzed the clinical characteristics of three patients with intestinal perforation.

Results

All patients receiving bevacizumab. Three of 217 patients occurred intestinal perforation after receiving bevacizumab. Patient no. 1 was 70 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab. Patient no. 2 was 59 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation after receiving bevacizumab, and recovered smoothly after symptomatic treatment. Patient no. 3 was 60 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab.

Conclusions

Patients with advanced colorectal cancer receiving bevacizumab are at risk of gastrointestinal perforation. The patient's age, gender and history of bowel obstruction may be associated with gastrointestinal perforation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intestinal PerforationColorectal NeoplasmsRectal NeoplasmsColonic NeoplasmsIntestinal ObstructionHumansFemaleAgedMiddle AgedBevacizumabRetrospective Studies

Stichwörter der Autor:innen

adverse reactionsbevacizumabcolorectal cancergastrointestinal perforation

Substanzen

Bevacizumab

Autor:innen und Institutionen

  • Department of Special Treatment I, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
  • Department of Hepatic Surgery II, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
  • Hepatobiliary Pancreatic Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Department of Colorectal and Anal Surgery, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Hepatic Surgery IV, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
  • Department of Hepatic Surgery I, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.

Förderung

  • the Program of Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Fang, K., Wang, J., Yuan, J., Sui, C., Zhi, J., Xia, Y., & Sun, M. (2024). Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer. Cancer Reports. https://doi.org/10.1002/cnr2.1952

Vancouver

Fang K, Wang J, Yuan J, Sui C, Zhi J, Xia Y, et al. Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer. Cancer Reports. 2024. doi:10.1002/cnr2.1952

BibTeX
@article{Fang2024,
  author = {Fang, Kunpeng and Wang, Jie and Yuan, Jianyong and Sui, Chengjun and Zhi, Jiajun and Xia, Yong and Sun, Minmin},
  title = {Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer},
  journal = {Cancer Reports},
  year = {2024},
  doi = {10.1002/cnr2.1952}
}
Kostenlos starten →